Royal Bank Of Canada Mei Pharma, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.21 - $0.35 $5 - $9	26 Added 9.52%	299 $0
Q4 2022 Feb 14, 2023	BUY	$0.22 - $8.4 $34 - $1,335	159 Added 139.47%	273 $0
Q3 2022 Nov 14, 2022	BUY	$0.41 - $8.8 $46 - $1,003	114 New	114 $0
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $3,618 - $5,599	-8,615 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $8,176 - $41,489	-15,142 Reduced 63.74%	8,615 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $31,438 - $45,471	13,493 Added 131.46%	23,757 $63,000
Q3 2021 Nov 15, 2021	BUY	$2.52 - $2.99 $4,919 - $5,836	1,952 Added 23.48%	10,264 $28,000
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $21,611 - $30,338	8,312 New	8,312 $24,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $370M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.